Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PRIMARY CHEMOTHERAPY IN BREAST-CANCER - CORRELATION BETWEEN TUMOR RESPONSE AND PATIENT OUTCOME
Autore:
FERRIERE JP; ASSIER I; CURE H; CHARRIER S; KWIATKOWSKI F; ACHARD JL; DAUPLAT J; CHOLLET P;
Indirizzi:
CTR JEAN PERRIN,58 RUE MONTALEMBERT,BP 392 F-63011 CLERMONT FERRA 1 FRANCE INSERM U71 CLERMONT FERRA FRANCE
Titolo Testata:
American journal of clinical oncology
fascicolo: 2, volume: 21, anno: 1998,
pagine: 117 - 120
SICI:
0277-3732(1998)21:2<117:PCIB-C>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Keywords:
BREAST CANCER; NEOADJUVANT CHEMOTHERAPY; PROGNOSIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
19
Recensione:
Indirizzi per estratti:
Citazione:
J.P. Ferriere et al., "PRIMARY CHEMOTHERAPY IN BREAST-CANCER - CORRELATION BETWEEN TUMOR RESPONSE AND PATIENT OUTCOME", American journal of clinical oncology, 21(2), 1998, pp. 117-120

Abstract

This study focused on the correlation between tumor response and patient outcome in 329 breast cancers treated with primary chemotherapy. There were 141 stage IIIB tumors, including 109 inflammatory carcinomas. Other malignancies (34 IIIA, 99 IIB, 55 IIA) were operable but considered to be too large (> 3 cm) for conservative surgery and received primary chemotherapy to avoid mastectomy. All received the AVCF regimen, comprising 4-week cycles of doxorubicin (30 mg/m(2)) day 1, vincristine (1 mg/m(2)) day 1, 5-fluorouracil (5-FU; 400 mg/m(2)) days 2 through 5, cyclophosphamide (300 mg/m(2)) days 2 through 5. In 189 cases, methotrexate (15 mg/m(2)) was added at day 2 and day 3. Patients received 6 cycles, then underwent locoregional treatment (surgery, radiotherapy, or both) according to tumor regression. The response rate was assessed by clinical, mammographic, and echographic examinations: a 50% rate of objective responses were noted, of which 15% were complete responses (tumor shrinkage allowed breast conservation in 68% of patients who had stages II or IIIA). For the whole population studied, median follow-up was 111 months (range, 60-196). One hundred fifty-seven patients had disease relapse (48 local, 14 contralateral, 95 distant). Kaplan-Meier estimates showed an increased 10-year overall survival for patients in complete response, as compared with noncomplete response: 70% versus 50% (p < 0.03). Complete response to neoadjuvant chemotherapyseems a good prognostic factor.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 04:13:07